文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-DOTATATE PET与111In-喷曲肽闪烁显像的Krenning评分比较及肿瘤负荷影响

111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden.
PubMed 文献 · J Nucl Med · 2019-03-08

该研究对150例前瞻性2期研究患者进行事后头对头比较,在同1周内分别行68Ga-DOTATATE PET/CT、111In-喷曲肽平面显像和SPECT/CT,由3名阅片者独立按Krenning评分分级。结果显示SSTR PET的Krenning评分显著高于平面显像和SPECT,尤其对≤2 cm病灶;小病灶在111In-喷曲肽显像中评分低,但SSTR PET评分不受病灶大小影响。

要点

  • SSTR PET的Krenning评分显著高于111In-喷曲肽平面显像和SPECT。
  • ≤2 cm病灶在111In-喷曲肽显像中评分低,SSTR PET不受病灶大小影响。
  • NETTER-1结果不能直接套用于小病灶患者。

核心结论

  • SSTR PET所得Krenning评分高于111In-喷曲肽,病灶≤2 cm时差异尤为明显。
  • 小病灶导致111In-喷曲肽显像Krenning评分偏低,但不影响SSTR PET的Krenning评分。
  • NETTER-1试验结果不能直接应用于小病灶患者。

研究设计与样本

  • 事后头对头比较,纳入前瞻性2期研究(NCT01967537)的150例患者。
  • 患者在同1周内行68Ga-DOTATATE PET/CT、111In-喷曲肽平面显像和SPECT/CT。
  • 由3名阅片者独立按Krenning评分对SSTR配体摄取进行分级。

主要发现

  • SSTR表达病灶(Krenning评分2-4)检出率:平面显像23%、SPECT 38%、SSTR PET 72%。
  • Krenning评分:SSTR PET为2.71±1.74,高于平面显像0.75±1.37(P<0.001)和SPECT 1.23±1.57(P<0.001)。
  • SSTR PET Krenning评分≥3的患者中,平面显像和SPECT对<2 cm病灶检出率分别为15%和24%,对≥2 cm病灶为78%和89%(P<0.001)。
  • 病灶>5 cm时,SSTR PET与111In-喷曲肽的Krenning评分几乎相当。
  • 阅片者间一致性:SSTR PET为0.79,高于平面显像0.67和SPECT 0.50。

关键数值与推荐

  • Krenning评分采用2-4分定义为SSTR表达病灶检出。
  • SSTR PET的Krenning评分均值2.71±1.74,平面显像0.75±1.37,SPECT 1.23±1.57。
  • SSTR表达病灶检出率:平面显像23%、SPECT 38%、SSTR PET 72%。
  • 病灶<2 cm时平面显像和SPECT检出率分别为15%和24%,≥2 cm时为78%和89%(P<0.001)。
  • 阅片者间一致性:SSTR PET 0.79、平面显像0.67、SPECT 0.50。

临床怎么用

  • 在评估SSTR表达用于PRRT准入时,SSTR PET可提供比111In-喷曲肽更高的Krenning评分。
  • 对小病灶(≤2 cm)患者,111In-喷曲肽显像可能低估SSTR表达,应考虑SSTR PET。
  • 引用NETTER-1准入标准时需注意其基于111In-喷曲肽显像,不直接适用于小病灶患者。

局限性

  • 本研究为事后分析,非前瞻性设计。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Eligibility for somatostatin receptor (SSTR) radionuclide therapy uses the qualitative Krenning score based on 111In-pentetreotide planar scintigraphy as was performed in the NETTER-1 trial. The purpose of this study was to determine the effect of using SSTR PET-based Krenning score in comparison to 111In-pentetreotide. Methods: This was a post hoc head-to-head comparison of 68Ga-DOTATATE-based and 111In-pentetreotide-based Krenning scores in 150 patients included in a prospective phase 2 study (NCT01967537). Patients were imaged using 68Ga-DOTATATE PET/CT, 111In-pentetreotide planar scintigraphy, and SPECT/CT within 1 wk. SSTR ligand uptake was graded using the Krenning score independently by 3 readers. Results: The detection rate of SSTR-expressing disease (Krenning scores 2-4) was 23%, 38%, and 72% with planar imaging, SPECT, and SSTR PET, respectively. The Krenning score was higher with SSTR PET (2.71 ± 1.74) than with planar imaging (0.75 ± 1.37; P < 0.001) or SPECT (1.23 ± 1.57; P < 0.001). In patients with a Krenning score of at least 3 on SSTR PET, the detection rate of planar imaging and SPECT was lower for lesions smaller than 2 cm than lesions 2 cm or larger: 15% and 24% versus 78% and 89%, respectively (P < 0.001). For lesions larger than 5 cm, Krenning scores between SSTR PET and 111In-pentetreotide were nearly equivalent. Lesion size did not have an impact on SSTR PET Krenning scores. Interreader agreement was higher for SSTR PET than for planar imaging or SPECT (0.79 vs. 0.67 and 0.50, respectively). Conclusion: SSTR PET results in higher Krenning scores than 111In-pentetreotide, particularly when lesions measured 2 cm or less. Small lesion size resulted in low Krenning scores using 111In-pentetreotide, but lesion size did not affect SSTR PET-based Krenning scores. The results of the NETTER-1 trial cannot be directly applied to patients with small lesions. Further study of peptide receptor radionuclide therapy in patients with small lesions negative on 111In-pentetreotide imaging and positive on SSTR PET is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hope TA, Calais J, Zhang L, et al. 111In-Pentetreotide Scintigraphy Versus 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. J Nucl Med. 2019. PMID: 30850506. doi:10.2967/jnumed.118.223016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。